The latest featured news from Pituitary World News
We are very pleased to announce our latest book on Prolactinomas. This is the 6th book in a series that includes tomes on Cushing’s, Hypopituitarism, Vasopressin Deficiency (formerly Diabetes Insipidus), Pituitary Adenomas, and Pituitary Disorders. The Prolactinomas book is available here and in all major book retailers.
How should clinicians define disease control, select therapy, and personalize treatment for people living with acromegaly? A new three-part podcast series from The Pituitary Society explores these questions through the lens of the updated international consensus recommendations on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37).
In this engaging discussion, we touch on why muscles stay weak in acromegaly even after the disease is under control, and why hypercortisolism keeps turning up in more people than anyone used to expect. Dr. Valassi’s earlier work on acromegaly and muscles got a lot of attention from PWN readers.
This is my conversation with Dr. Ken Ho, Professor at St. Vincent’s Hospital, Sydney and Garvan Institute of Medical Research, Sydney, Australia, on why a single word could change how pituitary patients are treated, and why leading endocrinologists are asking the WHO (World Health Organization) to reconsider.
I sat down with Dr. Leena Shahla, medical director of the Duke Pituitary Center to talk about the latest developments from ENDO 2026. Many in of our readers will remember her from an earlier Pituitary World News Podcast conversation with our co-founder, Dr. Lewis Blevins, on the tricky business of distinguishing pseudo-Cushing’s from the real thing. This time, the focus was the fast-moving world of acromegaly therapy.
For those of us living with pituitary and adrenal disease, the genetic and molecular information in tumors can help clarify an uncertain diagnosis, suggest whether an existing therapy is likely to work, and increasingly, point toward treatments designed specifically for the biology involved.
We ran into Sonnie Kim, Camurus’ head of Medical Affairs, at this year’s ENDO2026 conference in Chicago and asked her about the latest on CAM2029, the long-acting octreotide subcutaneous depot delivered by a pre-filled pen, built on the company’s FluidCrystal technology. The product is approved in Europe under the brand name Oczyesa and is still awaiting US approval.
In this conversation recorded at ENDO 2026 in Chicago a few weeks ago, we sit down with Dr. Kevin Yuen, medical director of the Barrow Pituitary Center in Phoenix, Arizona, to discuss one of the most challenging periods in pituitary care: the transition from pediatric to adult services. Dr. Yuen explains why these years are so vulnerable.
The annual international endocrine conference ENDO 2026, which just ended in Chicago, yielded a ton of information and new developments. We recorded 16 interviews with doctors, scientists, patient advocates, and industry representatives, so please stay tuned; they will be published in the next few days. Great, interesting information to come. Of particular note was Dr. Richard Auchus, Professor of Medicine at the University of Michigan, on the connection between Cortisol, difficult-to-treat hypertension, and type 2 diabetes…
In today’s LIVE-TALK podcast, we chat about our recently published series of books. We highlight Dr. Blevins’ prolific writing output in the PWN self-published book series, with five titles on pituitary adenomas, diabetes insipidus, Cushing’s, hypopituitarism, and pituitary disorders; a TSH-producing tumor book (in editing); a prolactinoma volume heading to the publisher; and an acromegaly book planned.
From Lewis S. Blevins, Jr. MD – The practice of medicine has undergone considerable change since I graduated from medical school in 1987. Some of the changes have been revolutionary in response to advances in
From J D Faccinetti – PWN co-founder and chief editor – Hypercortisolism, also known as Cushing’s syndrome – not to be confused with Cushing’s disease (more on that below), is far more common in people
I’m losing my patience with insurance companies and pharmacy benefit managers. They are destroying medicine in their pursuit of wealth for investors and C-suite executives. Many things we do, from diagnostic and laboratory tests to medications, are being denied.